Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening
Web of Science
AuthorSaville, M; Sultana, F; Malloy, MJ; Velentzis, LS; Caruana, M; Ip, ELO; Keung, MHT; Canfell, K; Brotherton, JML; Hawkes, D
Source TitleJournal of Clinical Microbiology
PublisherAMER SOC MICROBIOLOGY
University of Melbourne Author/sHawkes, David; Saville, Marion; Malloy, Michael; Sultana, Farhana; Velentzis, Louiza Sofia; Brotherton, Julia
AffiliationMelbourne School of Population and Global Health
Obstetrics and Gynaecology
Pharmacology and Therapeutics
Document TypeJournal Article
CitationsSaville, M., Sultana, F., Malloy, M. J., Velentzis, L. S., Caruana, M., Ip, E. L. O., Keung, M. H. T., Canfell, K., Brotherton, J. M. L. & Hawkes, D. (2019). Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening. JOURNAL OF CLINICAL MICROBIOLOGY, 57 (2), https://doi.org/10.1128/JCM.01239-18.
Access StatusOpen Access
This study demonstrates that the clinical sensitivity, specificity, and reproducibility of the novel cobas human papillomavirus (HPV) test on the cobas 6800 system for high-risk HPV types fulfills the criteria for use in population-based cervical screening. The criteria were formulated by an international consortium, using the cobas 4800 HPV test as a validated reference assay. The cobas HPV test detected over 98% of histologically confirmed cervical intraepithelial neoplasia grade 2+ (CIN2+) lesions in women age 30 years or older, with a specificity of 98.9% compared with the reference cobas 4800 test. Both the intra- and interlaboratory agreement for the cobas HPV test were 98%. The clinical performance of the cobas HPV test is comparable to those of longitudinally validated HPV assays and fulfills the criteria for its use in primary cervical screening.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References